Last reviewed · How we verify
Placebo (PLB) Oral
This drug has no known mechanism of action.
At a glance
| Generic name | Placebo (PLB) Oral |
|---|---|
| Also known as | Oral matching (to Bupropion) placebo tablets, Arm: Placebo Comparator - matched Placebo (PLB), Placebo |
| Sponsor | University of Texas Southwestern Medical Center |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action.
Approved indications
Common side effects
Key clinical trials
- Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder (PHASE3)
- Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans (PHASE2)
- Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal (PHASE2)
- Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder (PHASE3)
- Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients (PHASE3)
- Selenium Supplementation in Pregnancy (NA)
- A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine (PHASE1)
- Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (PLB) Oral CI brief — competitive landscape report
- Placebo (PLB) Oral updates RSS · CI watch RSS
- University of Texas Southwestern Medical Center portfolio CI